{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:38:26Z","timestamp":1792744706092,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>\n                      Recently approved by the United States Food and Drug Administration,\n                      <jats:sup>18<\/jats:sup>\n                      F-flurpiridaz for positron emission tomography (PET) myocardial perfusion imaging (MPI) enables high-quality assessment of myocardial blood flow (MBF). Its half-life of approximately 110\u00a0min supports regional distribution and allows unit-dose delivery. These features make this probe well suited for MBF quantitation and expand access to quantitative cardiac PET at smaller centers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>During pharmacologic stress, absolute MBF and myocardial flow reserve provide incremental diagnostic information beyond relative perfusion imaging. These measures have been validated across multiple methods and software platforms. Further study of this tracer under peak exercise may provide clinically relevant assessment of myocardial demand-induced changes in flow. Potential investigational approaches include artificial intelligence (AI)-derived virtual MBF, exercise-adjusted standardized uptake value (SUV) ratio-derived myocardial flow reserve (MFR) surrogate, and direct kinetic modeling during in-scanner ergometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>While conceptually promising, limitations inherent to exercise-based approaches in stress MBF and\/or MFR estimation highlight the need for pragmatic research strategies before potential clinical applicability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11886-026-02439-4","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:50:14Z","timestamp":1792741814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Myocardial Blood Flow Using 18F-flurpiridaz PET: Established Applications with Pharmacologic Stress and Roadmap for Exercise Stress Implementation"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7111-5268","authenticated-orcid":false,"given":"Farzana Z.","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6110-938X","authenticated-orcid":false,"given":"Piotr J.","family":"Slomka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8520-5843","authenticated-orcid":false,"given":"Ren\u00e9 R. Sevag","family":"Packard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"2439_CR1","doi-asserted-by":"publisher","first-page":"102175","DOI":"10.1016\/j.nuclcard.2025.102175","volume":"45S","author":"J Maddahi","year":"2025","unstructured":"Maddahi J. 18F flurpiridaz PET MPI: imaging characteristics and clinical trials. J Nucl Cardiol. 2025;45S:102175. https:\/\/doi.org\/10.1016\/j.nuclcard.2025.102175.","journal-title":"J Nucl Cardiol"},{"key":"2439_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jcmg.2025.03.011","volume":"18","author":"RRS Packard","year":"2025","unstructured":"Packard RRS, Pelletier-Galarneau M, Malhotra S, Dorbala S, Chen W, Dilsizian V. Established and emerging fluorine-18-labeled cardiac PET radiotracers. JACC Cardiovasc Imaging. 2025;18:815\u201333. https:\/\/doi.org\/10.1016\/j.jcmg.2025.03.011.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2439_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44161-024-00587-w","volume":"4","author":"RRS Packard","year":"2025","unstructured":"Packard RRS. The clinical promise of 18F-flurpiridaz PET imaging heralds a new frontier in the diagnosis and management of coronary artery disease. Nat Cardiovasc Res. 2025;4:1\u20134. https:\/\/doi.org\/10.1038\/s44161-024-00587-w.","journal-title":"Nat Cardiovasc Res"},{"key":"2439_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1053\/j.semnuclmed.2011.02.004","volume":"41","author":"M Yu","year":"2011","unstructured":"Yu M, Nekolla SG, Schwaiger M, Robinson SP. The next generation of cardiac positron emission tomography imaging agents: discovery of flurpiridaz F-18 for detection of coronary disease. Semin Nucl Med. 2011;41:305\u201313. https:\/\/doi.org\/10.1053\/j.semnuclmed.2011.02.004.","journal-title":"Semin Nucl Med"},{"key":"2439_CR5","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.2967\/jnumed.111.092528","volume":"52","author":"J Maddahi","year":"2011","unstructured":"Maddahi J, Czernin J, Lazewatsky J, Huang SC, Dahlbom M, Schelbert H, et al. Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest. J Nucl Med. 2011;52:1490\u20138. https:\/\/doi.org\/10.2967\/jnumed.111.092528.","journal-title":"J Nucl Med"},{"key":"2439_CR6","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.2967\/jnumed.114.141093","volume":"55","author":"RRS Packard","year":"2014","unstructured":"Packard RRS, Huang SC, Dahlbom M, Czernin J, Maddahi J. Absolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PET. J Nucl Med. 2014;55:1438\u201344. https:\/\/doi.org\/10.2967\/jnumed.114.141093.","journal-title":"J Nucl Med"},{"key":"2439_CR7","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1093\/ehjci\/jeab267","volume":"23","author":"RRS Packard","year":"2022","unstructured":"Packard RRS, Votaw JR, Cooke CD, Van Train KF, Garcia EV, Maddahi J. 18F-flurpiridaz positron emission tomography segmental and territory myocardial blood flow metrics: incremental value beyond perfusion for coronary artery disease categorization. Eur Heart J Cardiovasc Imaging. 2022;23:1636\u201344. https:\/\/doi.org\/10.1093\/ehjci\/jeab267.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2439_CR8","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1161\/CIRCULATIONAHA.108.797761","volume":"119","author":"SG Nekolla","year":"2009","unstructured":"Nekolla SG, Reder S, Saraste A, Higuchi T, Dzewas G, Preissel A, et al. Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model. Circulation. 2009;119:2333\u201342. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.797761.","journal-title":"Circulation"},{"key":"2439_CR9","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.2967\/jnumed.125.270873","volume":"66","author":"RRS Packard","year":"2025","unstructured":"Packard RRS, Maddahi J, Pelletier-Galarneau M, Al-Mallah MH, Coelho M, Dorbala S, et al. SNMMI\/EANM\/ASNC\/ACNM procedure standard\/practice guideline for 18F-flurpiridaz PET myocardial perfusion imaging and blood flow quantitation. J Nucl Med. 2025;66:1538\u201354. https:\/\/doi.org\/10.2967\/jnumed.125.270873.","journal-title":"J Nucl Med"},{"key":"2439_CR10","doi-asserted-by":"publisher","first-page":"102180","DOI":"10.1016\/j.nuclcard.2025.102180","volume":"45S","author":"RRS Packard","year":"2025","unstructured":"Packard RRS, de Kemp RA, Knuuti J, Moody JB, Renaud JM, Saraste A, et al. Quantitative approaches to 18F-flurpiridaz positron emission tomography image analysis. J Nucl Cardiol. 2025;45S:102180. https:\/\/doi.org\/10.1016\/j.nuclcard.2025.102180.","journal-title":"J Nucl Cardiol"},{"key":"2439_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/j.semnuclmed.2020.02.001","volume":"50","author":"MF Di Carli","year":"2020","unstructured":"Di Carli MF. PET perfusion and flow assessment: tomorrows\u2019 technology today. Semin Nucl Med. 2020;50:227\u201337. https:\/\/doi.org\/10.1053\/j.semnuclmed.2020.02.001.","journal-title":"Semin Nucl Med"},{"key":"2439_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1083\/jcb.48.3.673","volume":"48","author":"R Laguens","year":"1971","unstructured":"Laguens R. Morphometric study of myocardial mitochondria in the rat. J Cell Biol. 1971;48:673\u20136. https:\/\/doi.org\/10.1083\/jcb.48.3.673.","journal-title":"J Cell Biol"},{"key":"2439_CR13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/0022-2828(92)93381-s","volume":"24","author":"E Barth","year":"1992","unstructured":"Barth E, Stammler G, Speiser B, Schaper J. Ultrastructural quantitation of mitochondria and myofilaments in cardiac muscle from 10 different animal species including man. J Mol Cell Cardiol. 1992;24:669\u201381. https:\/\/doi.org\/10.1016\/0022-2828(92)93381-s.","journal-title":"J Mol Cell Cardiol"},{"key":"2439_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.2967\/jnumed.107.044727","volume":"49","author":"MC Huisman","year":"2008","unstructured":"Huisman MC, Higuchi T, Reder S, Nekolla SG, Poethko T, Wester HJ, et al. Initial characterization of an 18F-labeled myocardial perfusion tracer. J Nucl Med. 2008;49:630\u20136. https:\/\/doi.org\/10.2967\/jnumed.107.044727.","journal-title":"J Nucl Med"},{"key":"2439_CR15","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00259-021-05643-2","volume":"49","author":"Y Otaki","year":"2022","unstructured":"Otaki Y, Van Kriekinge SD, Wei CC, Kavanagh P, Singh A, Parekh T, et al. Improved myocardial blood flow estimation with residual activity correction and motion correction in 18F-flurpiridaz PET myocardial perfusion imaging. Eur J Nucl Med Mol Imaging. 2022;49:1881\u201393. https:\/\/doi.org\/10.1007\/s00259-021-05643-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2439_CR16","doi-asserted-by":"publisher","first-page":"102450","DOI":"10.1016\/j.nuclcard.2025.102450","volume":"52","author":"JM Renaud","year":"2025","unstructured":"Renaud JM, Moody JB, Vanderver MD, Poitrasson-Riviere A, Buckley CJ, Ficaro EP, et al. Improved diagnostic performance of 18F-flurpiridaz positron emission tomography myocardial blood flow quantification with automated dynamic motion correction. J Nucl Cardiol. 2025;52:102450. https:\/\/doi.org\/10.1016\/j.nuclcard.2025.102450.","journal-title":"J Nucl Cardiol"},{"key":"2439_CR17","doi-asserted-by":"publisher","first-page":"102072","DOI":"10.1016\/j.nuclcard.2024.102072","volume":"44","author":"V Builoff","year":"2025","unstructured":"Builoff V, Huang C, Kuronuma K, Wei CC, Fujito H, Otaki Y, et al. Automatic motion correction for myocardial blood flow estimation improves diagnostic performance for coronary artery disease in 18F-flurpiridaz positron emission tomography-myocardial perfusion imaging. J Nucl Cardiol. 2025;44:102072. https:\/\/doi.org\/10.1016\/j.nuclcard.2024.102072.","journal-title":"J Nucl Cardiol"},{"key":"2439_CR18","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1007\/s12350-021-02837-x","volume":"29","author":"A Poitrasson-Riviere","year":"2022","unstructured":"Poitrasson-Riviere A, Moody JB, Renaud JM, Hagio T, Arida-Moody L, Buckley C, et al. Impact of residual subtraction on myocardial blood flow and reserve estimates from rapid dynamic PET protocols. J Nucl Cardiol. 2022;29:2262\u201370. https:\/\/doi.org\/10.1007\/s12350-021-02837-x.","journal-title":"J Nucl Cardiol"},{"key":"2439_CR19","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.2967\/jnumed.124.269398","volume":"66","author":"RRS Packard","year":"2025","unstructured":"Packard RRS, Buckley C, Cooke CD, Moody JB, Renaud JM, Slomka P, et al. Comparison, agreement, and significance cutoffs of 18F-flurpiridaz PET myocardial blood flow quantitation methods and software packages. J Nucl Med. 2025;66:1674\u201382. https:\/\/doi.org\/10.2967\/jnumed.124.269398.","journal-title":"J Nucl Med"},{"key":"2439_CR20","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jacc.2023.08.016","volume":"82","author":"J Maddahi","year":"2023","unstructured":"Maddahi J, Agostini D, Bateman TM, Bax JJ, Beanlands RSB, Berman DS, et al. Flurpiridaz F-18 PET myocardial perfusion imaging in patients with suspected coronary artery disease. J Am Coll Cardiol. 2023;82:1598\u2013610. https:\/\/doi.org\/10.1016\/j.jacc.2023.08.016.","journal-title":"J Am Coll Cardiol"},{"key":"2439_CR21","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.2967\/jnumed.125.270997","volume":"67","author":"H Song","year":"2026","unstructured":"Song H, Xiang Z, Wang Y, Zhao J, Wen Y, Qin Z, et al. First Total-Body Kinetics Study of 18F-Flurpiridaz in Healthy Volunteers at Rest and Feasibility of Simplified Quantitative Strategies. J Nucl Med. 2026;67:1148\u201355. https:\/\/doi.org\/10.2967\/jnumed.125.270997.","journal-title":"J Nucl Med"},{"key":"2439_CR22","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2967\/jnumed.123.266858","volume":"65","author":"R Slart","year":"2024","unstructured":"Slart R, Bengel FM, Akincioglu C, Bourque JM, Chen W, Dweck MR, et al. Total-body PET\/CT applications in cardiovascular diseases: a perspective document of the SNMMI cardiovascular council. J Nucl Med. 2024;65:607\u201316. https:\/\/doi.org\/10.2967\/jnumed.123.266858.","journal-title":"J Nucl Med"},{"key":"2439_CR23","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s12350-020-02034-2","volume":"28","author":"JB Moody","year":"2021","unstructured":"Moody JB, Poitrasson-Riviere A, Hagio T, Buckley C, Weinberg RL, Corbett JR, et al. Added value of myocardial blood flow using 18F-flurpiridaz PET to diagnose coronary artery disease: the flurpiridaz 301 trial. J Nucl Cardiol. 2021;28:2313\u201329. https:\/\/doi.org\/10.1007\/s12350-020-02034-2.","journal-title":"J Nucl Cardiol"},{"key":"2439_CR24","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1001\/jamacardio.2017.2471","volume":"2","author":"I Danad","year":"2017","unstructured":"Danad I, Raijmakers PG, Driessen RS, Leipsic J, Raju R, Naoum C, et al. Comparison of coronary CT angiography, SPECT, PET, and hybrid imaging for diagnosis of ischemic heart disease determined by fractional flow reserve. JAMA Cardiol. 2017;2:1100\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2017.2471.","journal-title":"JAMA Cardiol"},{"key":"2439_CR25","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1093\/eurheartj\/ehy632","volume":"39","author":"GA de Waard","year":"2018","unstructured":"de Waard GA, Danad I, Petraco R, Driessen RS, Raijmakers PG, Teunissen PF, et al. Fractional flow reserve, instantaneous wave-free ratio, and resting Pd\/Pa compared with [15O]H2O positron emission tomography myocardial perfusion imaging: a PACIFIC trial sub-study. Eur Heart J. 2018;39:4072\u201381. https:\/\/doi.org\/10.1093\/eurheartj\/ehy632.","journal-title":"Eur Heart J"},{"key":"2439_CR26","doi-asserted-by":"publisher","first-page":"e018323","DOI":"10.1161\/CIRCIMAGING.125.018323","volume":"18","author":"DM Lopez","year":"2025","unstructured":"Lopez DM, Huck DM, Divakaran S, Brown JM, Weber BN, Lemley M, et al. Utility of 18F-flurpiridaz PET relative flow reserve in differentiating obstructive from nonobstructive coronary artery disease. Circ Cardiovasc Imaging. 2025;18:e018323. https:\/\/doi.org\/10.1161\/CIRCIMAGING.125.018323.","journal-title":"Circ Cardiovasc Imaging"},{"key":"2439_CR27","doi-asserted-by":"publisher","first-page":"102644","DOI":"10.1016\/j.nuclcard.2026.102644","volume":"58","author":"M Alwan","year":"2026","unstructured":"Alwan M, El Yaman A, Al Rifai M, Escobar S, Abbasi SF, Ghosn MG, et al. Optimizing protocol efficiency in [18F]flurpiridaz positron emission tomography myocardial perfusion imaging through dose ratio-driven reduction of relative residual activity. J Nucl Cardiol. 2026;58:102644. https:\/\/doi.org\/10.1016\/j.nuclcard.2026.102644.","journal-title":"J Nucl Cardiol"},{"key":"2439_CR28","doi-asserted-by":"publisher","first-page":"102674","DOI":"10.1016\/j.nuclcard.2026.102674","volume":"58","author":"FZ Ali","year":"2026","unstructured":"Ali FZ, Packard RRS. Protocol optimization for 18F-flurpiridaz positron emission tomography myocardial perfusion imaging to enhance clinical workflow. J Nucl Cardiol. 2026;58:102674. https:\/\/doi.org\/10.1016\/j.nuclcard.2026.102674.","journal-title":"J Nucl Cardiol"},{"key":"2439_CR29","doi-asserted-by":"publisher","unstructured":"Urs M, Kwiecinski J, Lemley M, Chareonthaitawee P, Ramirez G, Shanbhag A, et al. Virtual myocardial blood flow and flow reserve from static PET imaging using artificial intelligence. medRxiv. 2026. https:\/\/doi.org\/10.64898\/2026.02.03.26345376","DOI":"10.64898\/2026.02.03.26345376"},{"key":"2439_CR30","doi-asserted-by":"publisher","first-page":"102531","DOI":"10.1016\/j.nuclcard.2025.102531","volume":"53","author":"E Moulton","year":"2025","unstructured":"Moulton E, Gagliano L, Kaviani S, Klein R, deKemp R, Pelletier-Galarneau M. Artificial intelligence-enabled parametric mapping of myocardial blood flow with (82)Rb positron emission tomography compared to 18F-flurpiridaz perfusion imaging: a paired pilot study of image quality. J Nucl Cardiol. 2025;53:102531. https:\/\/doi.org\/10.1016\/j.nuclcard.2025.102531.","journal-title":"J Nucl Cardiol"},{"key":"2439_CR31","doi-asserted-by":"publisher","first-page":"102449","DOI":"10.1016\/j.nuclcard.2025.102449","volume":"52","author":"G Ramirez","year":"2025","unstructured":"Ramirez G, Lemley M, Shanbhag A, Kwiecinski J, Miller RJH, Kavanagh PB, et al. The REgistry of flow and perfusion imaging for artificial intelligence with positron emission tomography (REFINE PET): rationale and design. J Nucl Cardiol. 2025;52:102449. https:\/\/doi.org\/10.1016\/j.nuclcard.2025.102449.","journal-title":"J Nucl Cardiol"},{"key":"2439_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41746-026-02338-6","volume":"9","author":"W Zhang","year":"2026","unstructured":"Zhang W, Kwiecinski J, Shanbhag A, Miller RJH, Mostafavi S, Ramirez G, et al. Multicenter evaluation of interpretable AI for coronary artery disease diagnosis from PET biomarkers. NPJ Digit Med. 2026;9:154. https:\/\/doi.org\/10.1038\/s41746-026-02338-6.","journal-title":"NPJ Digit Med"},{"key":"2439_CR33","doi-asserted-by":"publisher","first-page":"102532","DOI":"10.1016\/j.nuclcard.2025.102532","volume":"54","author":"O Barrett","year":"2025","unstructured":"Barrett O, Shanbhag A, Zaid R, Miller RJH, Lemley M, Builoff V, et al. Incremental diagnostic value of artificial intelligence-derived coronary artery calcium in 18F-flurpiridaz positron emission tomography myocardial perfusion imaging. J Nucl Cardiol. 2025;54:102532. https:\/\/doi.org\/10.1016\/j.nuclcard.2025.102532.","journal-title":"J Nucl Cardiol"},{"issue":"Suppl 1","key":"2439_CR34","volume":"66","author":"K-Y Wu","year":"2025","unstructured":"Wu K-Y, Choueiry J, Lazewatsky J, Orlandi C, Packard RRS, Maddahi J, et al. Quantification of myocardial flow reserve using exercise stress F-18-flurpiridaz PET imaging [abstract]. J Nucl Med. 2025;66(Suppl 1):251377.","journal-title":"J Nucl Med"},{"key":"2439_CR35","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2967\/jnumed.110.083196","volume":"52","author":"HM Sherif","year":"2011","unstructured":"Sherif HM, Nekolla SG, Saraste A, Reder S, Yu M, Robinson S, et al. Simplified quantification of myocardial flow reserve with flurpiridaz F 18: validation with microspheres in a pig model. J Nucl Med. 2011;52:617\u201324. https:\/\/doi.org\/10.2967\/jnumed.110.083196.","journal-title":"J Nucl Med"},{"key":"2439_CR36","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1007\/s12350-018-01484-z","volume":"26","author":"J Maddahi","year":"2019","unstructured":"Maddahi J, Bengel F, Czernin J, Crane P, Dahlbom M, Schelbert H, et al. Dosimetry, biodistribution, and safety of flurpiridaz F 18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging. J Nucl Cardiol. 2019;26:2018\u201330. https:\/\/doi.org\/10.1007\/s12350-018-01484-z.","journal-title":"J Nucl Cardiol"},{"key":"2439_CR37","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1161\/01.cir.80.5.1328","volume":"80","author":"J Krivokapich","year":"1989","unstructured":"Krivokapich J, Smith GT, Huang SC, Hoffman EJ, Ratib O, Phelps ME, et al. 13N ammonia myocardial imaging at rest and with exercise in normal volunteers. Quantification of absolute myocardial perfusion with dynamic positron emission tomography. Circulation. 1989;80:1328\u201337. https:\/\/doi.org\/10.1161\/01.cir.80.5.1328.","journal-title":"Circulation"},{"key":"2439_CR38","first-page":"146","volume":"44","author":"CA Wyss","year":"2003","unstructured":"Wyss CA, Koepfli P, Mikolajczyk K, Burger C, von Schulthess GK, Kaufmann PA. Bicycle exercise stress in PET for assessment of coronary flow reserve: repeatability and comparison with adenosine stress. J Nucl Med. 2003;44:146\u201354.","journal-title":"J Nucl Med"},{"key":"2439_CR39","doi-asserted-by":"publisher","unstructured":"Shah NR, Cheezum MK, Veeranna V, Horgan SJ, Taqueti VR, Murthy VL, et al. Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function. J Am Heart Assoc. 2017;6. https:\/\/doi.org\/10.1161\/JAHA.116.005027","DOI":"10.1161\/JAHA.116.005027"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02439-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02439-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02439-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:50:16Z","timestamp":1792741816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02439-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2439"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02439-4","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"23 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Parts of Fig.\u00a0\n                      \n                      were generated using an AI-based image generation tool (Microsoft Copilot) based on author-developed scientific content which was subsequently reviewed for accuracy, edited, and the final version approved by all authors.","order":1,"name":"Ethics","label":"Use of Artificial Intelligence","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"FZA: no potential conflicts of interest. PJS: royalties from Cedars-Sinai; equity interest in APQ Health; consultant for Synektik; consultant for Novo Nordisk. RRSP: consultant and investigator-initiated research grant from GE HealthCare.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No animal or human subjects were used in this study.","order":3,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}}],"article-number":"115"}}